Primecap Management Co. CA Has $1.86 Million Position in Cerus Corporation $CERS

Primecap Management Co. CA trimmed its stake in shares of Cerus Corporation (NASDAQ:CERS) by 13.4% in the second quarter, Holdings Channel.com reports. The firm owned 1,315,400 shares of the biotechnology company’s stock after selling 203,800 shares during the quarter. Primecap Management Co. CA’s holdings in Cerus were worth $1,855,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Millennium Management LLC boosted its position in Cerus by 12.0% in the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after buying an additional 344,395 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Cerus by 38.6% during the second quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock worth $3,710,000 after buying an additional 733,683 shares in the last quarter. Ieq Capital LLC lifted its stake in shares of Cerus by 7.0% in the 1st quarter. Ieq Capital LLC now owns 2,320,796 shares of the biotechnology company’s stock valued at $3,226,000 after acquiring an additional 151,309 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Cerus by 6.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company’s stock valued at $2,466,000 after acquiring an additional 107,771 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after acquiring an additional 1,064,133 shares in the last quarter. Institutional investors own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CERS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cerus in a report on Wednesday, October 8th. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.00.

Cerus Price Performance

Cerus stock opened at $1.49 on Friday. The stock’s 50 day moving average is $1.52 and its 200 day moving average is $1.40. Cerus Corporation has a one year low of $1.12 and a one year high of $2.24. The firm has a market cap of $286.21 million, a P/E ratio of -14.90 and a beta of 1.67. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, November 6th. The biotechnology company reported $0.00 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.02. The business had revenue of $60.24 million during the quarter, compared to the consensus estimate of $55.12 million. Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. Cerus has set its FY 2025 guidance at EPS. As a group, research analysts expect that Cerus Corporation will post -0.08 EPS for the current year.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.